These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1252 related articles for article (PubMed ID: 25977460)

  • 1. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
    Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Nonnekens J; Chatalic KL; Molkenboer-Kuenen JD; Beerens CE; Bruchertseifer F; Morgenstern A; Veldhoven-Zweistra J; Schottelius M; Wester HJ; van Gent DC; van Weerden WM; Boerman OC; de Jong M; Heskamp S
    Cancer Biother Radiopharm; 2017 Mar; 32(2):67-73. PubMed ID: 28301262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
    Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Evaluation and Pilot Clinical Study of Al
    Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
    J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
    Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
    Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
    Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
    Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
    Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
    Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging.
    Harada N; Kimura H; Ono M; Saji H
    J Med Chem; 2013 Oct; 56(20):7890-901. PubMed ID: 24063417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
    Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of
    Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
    Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.